refresher: how vaccines work; vaccine research today jerald c. sadoff md aids vaccine 2009...
TRANSCRIPT
Refresher: How Vaccines Work; Vaccine Research Today
Jerald C. Sadoff MD
AIDS Vaccine 2009 Journalist Scholarship Training Overview
October 18th 2009 Paris, France
AERAS GLOBAL TB VACCINE FOUNDATION
Topics to be covered
• Refresher: How Vaccines Work
• Basic principles in developing vaccines
• Vaccine Research Today
AERAS GLOBAL TB VACCINE FOUNDATION
Refresher: How Vaccines Work
• The general answer
• The battle between the bugs and us
• Their Genes and our Genes
• Timing and location are everything
AERAS GLOBAL TB VACCINE FOUNDATION
The general answer how vaccines work
• Vaccines work by fooling the body into thinking it is infected with a bug so that next time when it sees the real thing it will be ready faster with a more powerful response
• Sometimes it gets the body to do something different and better then if it were naturally infected
AERAS GLOBAL TB VACCINE FOUNDATION
The Battle Between Us and the Bugs:What we can do
• We recognize them as something different not belonging inside the body
• Once recognized we try and kill them
• We have two systems of doing this:– The Innate system– The Cognate system
AERAS GLOBAL TB VACCINE FOUNDATION
The Innate System• Ancient system found in almost all living
things in some form• Recognizes patterns in pieces of the bugs
rather then specific pieces• Immediate but no memory for next time• Poisons released quickly that kill
everything around • Massive numbers of all kinds of cells called
in rapidly that eat what they encounter (called inflammation)
AERAS GLOBAL TB VACCINE FOUNDATION
Cognate System
• Newer more sophisticated system found in higher animals which is dependent on the innate system
• Recognizes very specific parts of the bug called antigens or epitopes
• Comes up slower if hasn’t seen it before
• It remembers from one time to the next
• Its weapons: antibodies and T cells recognize and kill very precisely
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccines induce the cognate system to remember, recognize, and kill viruses, bacteria, parasites or cancer cells
AERAS GLOBAL TB VACCINE FOUNDATION
The cognate system has 3 weapons:
1. Antibodies
2. White cells: Macs and Polys
3. White cells: T cells
AERAS GLOBAL TB VACCINE FOUNDATION
Antibodies
• Antibodies are proteins floating in our fluids and organs everywhere they can get
• At one end they recognize and stick on the surface of the bug
• When they bind bad things happen to the bug
AERAS GLOBAL TB VACCINE FOUNDATION
White cells: Macs and Polys
• Recognize the back end of the antibody stuck on the surface of the bug
• They use the antibodies like a zipper to close around the bug and eat it
• Once the bug is inside the cell its held in a bag and poisons are dumped in that kill it
AERAS GLOBAL TB VACCINE FOUNDATION
White cells: T cells
• Recognize our cells that have been infected by bacteria, viruses or parasites
• They get very close to the infected cell
• They secrete signals to the cell in very high concentrations that tell the cell to kill the bug
• Some of these T cells are memory cells that live a long time and some are effectors that are out in the tissues ready to pounce
AERAS GLOBAL TB VACCINE FOUNDATION
CD 4 T cell
CD 8 T cell
TH1 TH2 TH1 TH2
IFN-γ
IL-2TNF-α
IL-4
B - cell
antibodies
DTP, Hib, Pneumococcus, Measles, Polio, Hep B,
Rotavirus, HPV, Malaria TB, Malaria, HIV
Central or
Effector
Memory
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the Bugs: What they do
• They protect themselves from innate White cell engulfment and killing– Bacteria like Pneumococcus build thick walls
of sugar on their outsides that white cells cant engulf without the zipper of antibody – basis of the new pneumococcal vaccine
– TB organisms poison the bag they are in inside the cell so they cant be killed once inside
– Viruses like varicella hide in the nerves where white cells cant go
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the Bugs: What they do
• They move rapidly from one site to another so they are gone by the time the cognate system has responded– The malaria parasite is only in the blood for
less then a minute before it gets to the liver and then it changes so adaptive antibody isnt made
– It only stays in the liver for 10-14 days so that adaptive T cells are too slow
– The new malaria vaccine induces both antibody and T cells that are ready for it
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the Bugs: What they do
• They avoid the cognate T cell response by changing the ability of the cells they have infected to show they are infected– Measles, CMV and HIV all turn down the
ability of the infected cells to put pieces of the virus on its surface so that a cognate response is dampened
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the BugsTheir Genes and Our Genes
• They can change their genes rapidly because– They reproduce so fast– Sometimes like HIV they don’t reproduce very
accurately– They are a population attacking us not an
individual while we tend to be concerned about protecting each individual in our population
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the BugsTheir Genes and Our Genes
• We cant change our genes rapidly• We have a lot of genes
– We have genes to make antibodies that can recognize just about everything including plastic that doesn’t exist in nature
– We have genes for T cells that can recognize just about everything but each individual is unique on what pieces of viruses can be presented
• We can slowly change our antibody genes
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the Bugs: What they do• They can change so rapidly that they can
out run the cognate responses– HIV changes its surface variable regions so that
it avoids neutralizing antibody that develops• About 25% of humans eventually develop broad
neutralizing antibodies
– HIV changes the epitopes that are recognized by T cells within 10-20 days of first infecting humans thus avoiding that cognate response
• HIV can eventually find something that it human host cant respond to
AERAS GLOBAL TB VACCINE FOUNDATION
Battle with the Bugs: What they do• They misdirect the cognate system to
immunodominant antigens that they can change and away from antigens they cant change– Gonorrhea and E. coli pilus antigens highly
variable and immunodominant – distract from tip proteins that are required for attachment and sex
– HIV gp120 variable regions are B cell dominant and can vary rapidly
– HIV subdominant T cell antigens protect in the few animals that recognize them (Watkins)
AERAS GLOBAL TB VACCINE FOUNDATION
Timing and Location are Everything
• Timing - Vaccines work because the cognate response after vaccination is much faster when the bug is first seen then what occurs if it has to develop from scratch– Pneumococcal anti sera given within 3 days of
hospitalization 40% survival after 3 days no survival– Most vaccines have very little effect after the infection
has progressed since the system is already mounting a cognate response due to the infection
• Rabies is an exception - following a rabid animal bite the virus travels slowly up the nerve to the brain – immediate immunization can save your life if the immunity develops before the virus gets there, that’s why a bite on the face is worse then the arm
AERAS GLOBAL TB VACCINE FOUNDATION
Timing and Location are Everything
• Location is important because the cognate immune response has to get to the pathogen rapidly to be effective– Only 4 of 8 sets of T cells directed exactly at
the same piece of malaria worked to protect mice from malaria
– The 4 that worked are the one that got to the liver
AERAS GLOBAL TB VACCINE FOUNDATION
Studies with NIH VRC – Bob Seder, Mario Roederer
AERAS GLOBAL TB VACCINE FOUNDATION
Timing and Location are Everything
• An example of where timing and location are both thought to be critical is the protection induced by CMV vaccine against SIV infection to be further presented at this meeting by Louis Picker
• The effector T cells induced by this vaccine are not only ready to kill at the time of infection but they are already located where the virus goes.
AERAS GLOBAL TB VACCINE FOUNDATION
Basic Principles
• Use what the disease gives you
• Correlates and Surrogates make everything easy
• When everything else fails – Proof of Principle studies and bootstrapping
• Manufacturing – Vaccines are not iPods
• Assays rule
• Eternal triangle of risk vs time vs resources
AERAS GLOBAL TB VACCINE FOUNDATION
What the disease gives you
• Epidemiology –– Hemophilus type B – no disease till 4-6 month– Rotavirus – 2nd infection with different type– Zoster – more disease >65 years of age
• High Attack rate –– Rotavirus - efficacy in 400 children– Malaria – efficacy in 2000 children
AERAS GLOBAL TB VACCINE FOUNDATION
What the disease gives you
• Animal Model – – Hep B - Non Human Primate– Pnumococcus, Hemophilus,– TB – (?) low dose NHP challenge– HIV- (?) SIV low challenge dose
AERAS GLOBAL TB VACCINE FOUNDATION
What the disease gives you
• Possibility of Human Challenge studies– Shigella– Cholera– Malaria– HIV (?)
AERAS GLOBAL TB VACCINE FOUNDATION
Basic Principles
• Use what the disease gives you
• Correlates and Surrogates make everything easy
• When everything else fails – Proof of Principle studies and bootstrapping
• Manufacturing – Vaccines are not iPods
• Assays rule
• Eternal triangle of risk vs time vs resources
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
AERAS GLOBAL TB VACCINE FOUNDATION
Basic Principles
• Use what the disease gives you
• Correlates and Surrogates make everything easy
• When everything else fails – Proof of Principle studies and bootstrapping
• Manufacturing – Vaccines are not iPods
• Assays rule
• Eternal triangle of risk vs time vs resources
AERAS GLOBAL TB VACCINE FOUNDATION
RISK RESOURCES
TIME
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccine Research Today
• Antigens– Reverse Engineering– Bioinformatics– Epitopes
• Vaccine Delivery– Adjuvants– Non-replicating vectors– Replicating vectors
AERAS GLOBAL TB VACCINE FOUNDATION
Reverse Engineering
• Utilizing molecular modeling and immune responses in protected volunteers to down select from thousands of possible proteins
• Limited number of proteins put in mouse or other small animal studies
• Recent promising examples:– Common Group B meningococcal protein– Common Pneumococcal protein– Common Staphylococcal protein
AERAS GLOBAL TB VACCINE FOUNDATION
Reverse Engineering – Structural studies
• Understanding the detailed molecular structure of a target protein and its interaction with antibody design an immunogen to induce that antibody
• Influenza and HIV tremendous current work– Identified binding regions of monoclonals that
neutralize somewhat broadly including new ones that bind V3 stem
– So far unsuccessful in designing immunogen
AERAS GLOBAL TB VACCINE FOUNDATION
Bioinformatics
• Using scoring systems with internal validation combine all of the information about antigen candidates to select promising antigens for inclusion in vaccine vector
• Example: TB antigens for inclusion in a recombinant BCG for over-expression
AERAS GLOBAL TB VACCINE FOUNDATION
Scoring of Antigens Over-expressed/Up-regulated in AERAS-427 – From List of Top 45
Rv
312
7R
v2
005
cR
v3
873
Rv
262
6c
Rv
203
2R
v0
288
Rv
188
6c
Rv
203
1c
Rv
086
7c
Rv
100
9R
v2
623
Rv
245
0c
Rv
173
8
Rv
202
9c
Rv
200
6R
v1
813
cR
v1
349
Rv
117
4c
Rv
190
8c
Rv
082
4c
Rv
313
1R
v3
130
cR
v0
079
Rv
380
4c
Rv
198
0c
Rv
262
8R
v0
685
Rv
238
9c
Rv
199
6R
v1
733
c
Rv
262
9R
v1
793
Rv
116
9c
Rv
113
0R
v0
467
Rv
334
7c
Rv
313
2c
Rv
203
0c
Rv
192
6c
Rv
387
5R
v2
744
cR
v2
620
cR
v1
884
cR
v2
780
Rv
262
7c
32/4
5 to
p s
cori
ng
anti
gen
s b
y b
ioin
form
atic
s an
alys
is
dir
ectl
y ov
er-e
xpre
ssed
or
up
-reg
ula
ted
in A
ER
AS
-427
Rv
202
9c
AERAS GLOBAL TB VACCINE FOUNDATION
Epitopes
• Fundamental problem in B and T cell based vaccines is epitope selection to cover the variety of pathogens that might be encountered
• Second problem is the virus changing its epitopes
• Third problem is immunodominance of some epitopes over others
AERAS GLOBAL TB VACCINE FOUNDATION
Epitope Diversity
• The approach with Pneumococcal, rotavirus and HPV vaccines is to make multiple serotypes (up to 16 for Pneumo) with the broadest epidemiologic coverage
AERAS GLOBAL TB VACCINE FOUNDATION
Epitope Diversity- HIV
• Informatics approach to combine all known variablility in the data base with natural segments and maximize coverage– Criticism of this is that the variability is escape
to variants that cant be responded to – That this does represent incoming virus
• Search for epitopes that cant vary because of their function
AERAS GLOBAL TB VACCINE FOUNDATION
Epitope Immunodominance- HIV
• Utilization of subdominant antigens in absence of dominant antigens
• Sequential immunization
• Immunization with separate vaccines
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccine Delivery - Adjuvants
• Adjuvants stimulate the innate system – mainly through toll receptors
• Several new adjuvants in clinical trials
• AS04 with flu vaccines responses in 200-800 range compared to 20-60 for most flu vaccine
• AS01-E in malaria and TB vaccines provide very high CD4 T cells in humans
• IC-31 in TB vaccines induce CD4 T cells
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccine Delivery – Non-replicating vectors
• Vaccinia Based: NYVAC, ALVAC, MVA– HIV- Alvac part of Thai trial– TB – MVA AERAS-485 in a 2800 subject
Phase IIB efficacy trial in Cape Town S, Africa
• Adeno based: Ad5, Ad35, Chimp Adeno– HIV-
• Ad 5 – Merck NIH HIV trial, • Ad 5 - Current VRC trial
– Malaria -Chimp Adeno – prime for MVA boost – TB – Ad35 induced high CD8 T cells
AERAS GLOBAL TB VACCINE FOUNDATION
ITRITR E2B E2A E4
E1 L1-L3 E3L4 L5
ITRITR E2B E2A E4
E1 L1-L3 E3L4 L5
Genomic Structure
Ad35 Viral VectorTargets CD46 onHuman Dentritic CellsLow African seroprevalence (<2% with neut >200)E1 & Part of E3 deleted• Makes room for TB antigens (85A, 85B, 10.4)• Can’t replicate in humansGrows to high titer inPerC6 cells• Ad5 E1 in PerC6
chromosome• Ad5 E4 Orf6, 6/7
put in Ad35• Ad35 pIX put back
AERAS GLOBAL TB VACCINE FOUNDATION
PR
EL
IMIN
AR
Y D
AT
A –
10
DE
C 2
00
8
Aeras Study C-008-402DSMO subtracted Ag85A/b CD8 Response
BCG/AERAS-402 (3x10^10 vp)
0 84 91 98 112 119 126 140 182
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
BCG 402 402
%C
D8 R
esp
on
se BC
G im
mu
niz
ed
Ad
ult
s S
t L
ou
is
AERAS GLOBAL TB VACCINE FOUNDATION
Replicating Vectors
• Replicating vectors have the advantage of longer antigen production and possibly more effector cells
• Recombinant BCG: – Persists for around 40 days – Appears to be a good prime for protein or viral booster
• Yellow Fever– Being used as a vector for dengue vaccine now in
phase II trials– Being explored for HIV with promising NHP data
AERAS GLOBAL TB VACCINE FOUNDATION
Replicating Vectors - CMV
• Persists throughout the life of the animal• Down regulates the Class I so can re-infect• Induces subdominant antigens• Induces primarily effector memory T cells• Prevents productive SIV infection in low
dose NHP challenge• Safety issues as a human vaccine
– Birth defects in new borns– Liver and potential heart disease
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccines I Have Helped Develop
• Licensed (10)– Hep A (VAQTA)– Hemophilis type B (Liquid Pedvax)– Hemophilus type B – Hep B (Comvax)– Varicella (4 degree Varivax)– Measles-Mumps-Rubella- Varicella (ProQuad)– Hib-HepB-DPT-IPV (Hexavac)– Zoster (ZostaVax)– Rotavirus (Rota Teq)– Human Pappiloma Virus (Gardasil)– Cholera (Dukoral)
AERAS GLOBAL TB VACCINE FOUNDATION
Vaccines I Have Helped Develop
• Phase III– Malaria (RTS,S) ongoing– Cholera (Peru 15) beginning
• Phase IIB– Shigella (John Robbins - Polysaccharide conjugate) - successful– Gonorrhea (Pili vaccine) – failed– Pseudomonas E. Coli Klebsiella (Passive Aby) failed– HIV (Adeno Vectored Gag, Pol, Nef) – failed– TB (MVA85A-AERAS-485) – ongoing– TB (AERAS-402) – ongoing
• Phase II– TB (GSK- M72) - ongoing– TB (AERAS- 404 HyVac4 SSI/Sanofi) - Ongoing